Consent:

• At least one legally authorized guardian must provide written informed consent
• In some jurisdictions or high-risk trials, both parents may be required
• Consent forms must be written in language understandable to guardians

2. Child Assent:

• Assent means a child’s affirmative agreement to participate in the trial
• Should be obtained from children typically aged 7 years and above
• Assent forms should be age-appropriate in vocabulary and format
• Refusal to assent must be respected, even if parents have consented

Documentation of both guardian consent and child assent must be maintained in the site file per pharmaceutical SOP guidelines.

Ethics Committee Requirements for Pediatric Trials:

Before enrolling pediatric subjects, Ethics Committees (ECs) must:

• Approve separate ICFs and assent forms
• Review justification for including children in the trial
• Evaluate risk-benefit ratio with pediatric safety in mind

EC approvals must be specific for age ranges, consent formats, and oversight mechanisms as per CDSCO or EMA regulations.

Consent Considerations in Geriatric Trials:

Geriatric participants (typically aged 65 and older) may have varying levels of cognitive function, hearing or vision impairments, and multiple comorbidities. The informed consent process must address:

• Language clarity—use large fonts and plain text
• Physical support—provide glasses, magnifiers, or hearing aids as needed
• Cognitive capacity—screen for dementia or memory impairments
• Voluntariness—ensure freedom from coercion by caregivers

Investigators should tailor communication methods and verify understanding using tools such as the teach-back method or comprehension checklists.

Assessing Capacity in Geriatric Participants:

Before enrolling elderly subjects, investigators must assess their ability to:

• Understand study information
• Appreciate the potential risks and benefits
• Reason about their decision
• Communicate a clear choice

If capacity is questionable, a legally authorized representative (LAR) must provide consent, and the participant may provide assent if feasible. This should be documented thoroughly in compliance with clinical trial documentation.

Documentation Best Practices:

For both pediatric and geriatric subjects, proper documentation is essential:

• Record the version of ICF or assent form used
• Include details of the consenting individual (parent, guardian, LAR)
• Note if translations or witnesses were used
• Document the rationale for using an LAR, if applicable
• File the consent/assent forms in the Investigator Site File (ISF)

Sites must ensure alignment with the GMP documentation and GCP-compliant audit expectations.

Staff Training and Delegation:

Only trained and delegated personnel should handle consent for vulnerable populations. Training should cover:

• Communicating with children and older adults
• Using tools to assess cognitive and emotional maturity
• Recognizing signs of distress or coercion
• Properly completing consent and assent forms

Training records and delegation logs should be kept audit-ready as per validation master plans.

Special Considerations for Re-Consent:

Re-consenting may be necessary in the following scenarios:

• Pediatric participant reaches legal age during the study
• Geriatric participant’s cognitive status changes significantly
• Protocol amendments affecting safety or procedures

Sites must track age transitions and maintain up-to-date consent documentation accordingly.

Regulatory and Ethical Oversight:

Regulatory bodies expect additional safeguards for vulnerable subjects. These include:

• Clear justification for including children or elderly
• Adapted consent materials approved by ECs
• Compliance with local laws and international guidelines

Refer to pharma regulatory compliance protocols for study-specific adaptations.

Conclusion:

Managing informed consent in pediatric and geriatric trials requires sensitivity, customization, and strict adherence to regulatory standards. Whether obtaining parental consent and child assent, or verifying an elderly patient’s capacity to consent, clinical teams must uphold ethical integrity at every step. Proper documentation, staff training, and regulatory engagement are vital to safeguarding these vulnerable populations while ensuring trial validity and success.